LOW FEASIBILITY OF SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH DIABETES MELLITUS IN ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Kogure, Yoshihito [1 ]
Hori, Kazumi [1 ]
Funahashi, Yoriko [1 ]
Oka, Saori [1 ]
Tsuboi, Rie [1 ]
Adachi, Takashi [1 ]
Ryuge, Misaki [1 ]
Murata, Naohiko [1 ]
Kitagawa, Chiyoe [1 ]
Oki, Masahide [1 ]
Saka, Hideo [1 ]
机构：
[1] Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; Chemotherapy; diabetes mellitus;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1182 / S1183
页数：2
相关论文
共 50 条
  • [31] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [32] BIOMARKERS OF TORCH TRIAL ON FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Tsao, M. S.
    Gallo, C.
    Saieg, M.
    Santos, G. D. C.
    Gebbia, V.
    Perrone, F.
    Butts, C.
    Ciardiello, F.
    Feld, R.
    Gridelli, C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S59 - S59
  • [33] A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
    Kotsakis, Athanasios
    Hatzidaki, Dora
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Bozionelou, Vasiliki
    Androulakis, Nikolaos
    Kalbakis, Kostas
    Saridaki, Zacharenia
    Georgoulias, Vassilis
    Agelaki, Sophia
    ANTICANCER RESEARCH, 2010, 30 (10) : 4335 - 4342
  • [34] Costs of managing toxicities in advanced non-small cell lung cancer with pemetrexed compared with docetaxel as second-line chemotherapy
    Aristides, M
    Jackson, D
    Liepa, AM
    Leighl, NB
    Shepherd, F
    VALUE IN HEALTH, 2003, 6 (06) : 734 - 735
  • [35] Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine
    De Pas, T
    de Braud, F
    Mandalà, M
    Curigliano, G
    Catania, C
    Ferretti, G
    Sozzi, P
    Solli, P
    Goldhirsch, A
    LUNG CANCER, 2001, 31 (2-3) : 267 - 270
  • [36] GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
    Yang, M.
    Tan, E. C.
    Chen, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
  • [37] Considerations for second-line therapy of non-small cell lung cancer
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    ONCOLOGIST, 2008, 13 : 28 - 36
  • [38] Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Braillon, Alain
    LUNG CANCER, 2018, 122 : 257 - 257
  • [39] Second-line envafolimab and beyond in locally advanced or metastatic non-small cell lung cancer
    Guan, M.
    Shi, Q.
    ANNALS OF ONCOLOGY, 2024, 35
  • [40] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    LUNG CANCER, 2005, 49 : S248 - S248
12345